A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD)

Clinical Trial ID NCT01682083

PubWeight™ 17.30‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01682083

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013 1.90
2 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
3 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
4 Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012 1.16
5 B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol 2013 1.14
6 Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist 2013 1.08
7 Isolation and molecular characterization of circulating melanoma cells. Cell Rep 2014 1.02
8 Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther 2014 0.92
9 Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene 2015 0.90
10 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
11 A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. Clin Cancer Res 2015 0.88
12 Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther 2014 0.86
13 Targeted therapy; from advanced melanoma to the adjuvant setting. Front Oncol 2013 0.79
14 Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol 2015 0.78
15 MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther 2015 0.77
16 Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol 2015 0.77
17 New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf 2014 0.77
18 Malignant Melanoma. Healthcare (Basel) 2013 0.75
Next 100